Aileron Therapeutics sharestarget doubled by Ladenburg Thalmann
- ByInvesting.com
- •
Aileron Therapeutics, Inc. is a clinical-stage chemoprotection oncology company. It is focused on developing medicines to make chemotherapy safer. Its ALRN-6924 product is a MDM2/MDMX dual inhibitor that leverages its peptide drug technology, which is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the chemoprotective agent in clinical development, which focused on treating patients with p53-mutated cancers. It is developing ALRN-6924 to selectively protect healthy cells in patients with cancers that harbor p53 mutations to reduce or eliminate chemotherapy-induced side effects without interrupting chemotherapy’s destruction of cancer cells. It stabilizes peptides by stapling them with hydrocarbon bonds into their natural alpha-helical conformation. ALRN-6924 can pause cell division in cells with wild type, p53, include normal bone marrow cells and ALRN-6924 has no activity against cancer cells with mutations in p53.